RayKnowChina Research Map
Shortlist0

Guangxi Medical University

广西医科大学

NanningUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
5.2%Leads about 1 in 19 of China's research papers on NPC

Led 124 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
8
Research papers it led
124
Trials it led
19
Share of China's trials
3.2%
Share of the world's papers
3.8%
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025
ThemesRadiotherapy techniqueImaging & AIInduction / concurrent chemotherapy

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University54
  2. Guangxi Medical University Cancer Hospital48
  3. Second Affiliated Hospital of Guangxi Medical University4
  4. Fourth Affiliated Hospital of Guangxi Medical University3
  5. Sixth Affiliated Hospital of Guangxi Medical University2
  6. Wuming Hospital, Guangxi Medical University Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of modified Baduanjin exercise on nutritional status in patients with nasopharyngeal carcinoma: a randomized controlled trial.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  2. Scheduling radiotherapy for patients with nasopharyngeal carcinoma in the corresponding time window can reduce radiation-induced oral mucositis: A randomized, prospective study.2023Cancer medicineRCTFree full text
  3. The application of the PDCA cycle in the nutritional management of patients with nasopharyngeal carcinoma.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  4. Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study.2023Journal of cancer research and clinical oncologyRCTFree full text
  5. Association of Epstein-Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma.2022Future oncology (London, England)RCT
Trials on ClinicalTrials.gov6
  1. Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCRecruitingNCT07459296Lead sponsorPhase 3Start 2026-03
  2. Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal CarcinomaNot yet recruitingNCT07303283Lead sponsorPhase 2Start 2026-09
  3. Impacted Tooth Management and Osteoradionecrosis Risk in NPCNot yet recruitingNCT07764887Lead sponsorN/AStart 2026-08
  4. Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal CarcinomaNot yet recruitingNCT06680115Lead sponsorPhase 2Start 2024-11
  5. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After ChemoradiotherapyRecruitingNCT05892354Lead sponsorN/AStart 2023-06
  6. Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal CarcinomaRecruitingNCT05717790Lead sponsorN/AStart 2022-12

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.3%Leads under 1 in 100 of China's research papers on ESCC

Led 8 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 3320242025: 112025
ThemesMolecular markers & genomicsRadiotherapyNeoadjuvant & combined treatment

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University4
  2. Guangxi Medical University Cancer Hospital3
  3. Second Affiliated Hospital of Guangxi Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. The predictors of lymphopenia and its effects on survival in locally advanced esophageal squamous cell carcinoma.2024Cancer biology & therapyFree full text
  2. Adjuvant treatment patterns for pT3N0M0 esophageal cancer undergoing surgery.2024Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  3. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.2024Frontiers in immunologyFree full text
  4. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis.2021BMC cancerFree full text
  5. Macrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation.2025Cancer medicineFree full text
Trials on ClinicalTrials.gov6
  1. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  2. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  3. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  4. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  5. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  6. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
2.6%Leads about 1 in 39 of China's research papers on HCC

Led 378 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
4
Research papers it led
378
Trials it led
29
Share of China's trials
2.0%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 1120242025: 002025
ThemesRecurrence & prognosisImaging, AI & early detectionSurgery & liver transplant

Hospitals counted here

  1. Guangxi Medical University Cancer Hospital149
  2. First Affiliated Hospital of Guangxi Medical University134
  3. Second Affiliated Hospital of Guangxi Medical University16
  4. Eighth Affiliated Hospital of Guangxi Medical University4
  5. Liuzhou People's Hospital, Guangxi Medical University Counted in the group total3
  6. Fourth Affiliated Hospital of Guangxi Medical University Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study.2024Langenbeck's archives of surgeryRCT
  2. Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study.2023La Radiologia medicaRCTFree full text
  3. Nomograms for postsurgical extrahepatic recurrence prediction of hepatocellular carcinoma based on presurgical circulating tumor cell status and clinicopathological factors.2023Cancer medicineRCTFree full text
  4. Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus.2022Annals of hepatologyRCT
  5. Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy.2022BMC gastroenterologyRCTFree full text
Trials on ClinicalTrials.gov6
  1. Adjuvant TACE in HCC With High-risk Recurrence FactorsRecruitingNCT07417397Lead sponsorPhase 3Start 2026-02
  2. Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCCRecruitingNCT05062837Lead sponsorPhase 2/Phase 3Start 2021-06
  3. Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular CarcinomaRecruitingNCT05221398Lead sponsorStart 2019-03
  4. Conversion or Neoadjuvant Therapy in Hepatocellular CarcinomaRecruitingNCT06405321Lead sponsorStart 2019-01
  5. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  6. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.7%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 68 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
1
Research papers it led
68
Trials it led
2
Share of China's trials
0.1%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025
ThemesImaging & AIPeritoneal spread & advanced diseaseNutrition & recovery

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University46
  2. Guangxi Medical University Cancer Hospital12
  3. Second Affiliated Hospital of Guangxi Medical University Counted in the group total2
  4. Affiliated Minzu Hospital of Guangxi Medical University1
  5. Third Affiliated Hospital of Guangxi Medical University Counted in the group total1
  6. Fourth Affiliated Hospital of Guangxi Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation.2022TrialsRCTFree full text
  2. Neoadjuvant Docetaxel, Oxaliplatin, and S-1 in Resectable Advanced Gastric Cancer.2021Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  3. Body Composition Decrease and Impact on Clinical Outcome in Gastric Cancer Patients Undergoing Radical Gastrectomy After Neoadjuvant Treatment.2025Nutrition and cancer
  4. Integrating visceral protein ratios and mid-arm circumference predicts survival and malnutrition in gastric cancer.2025Scientific reportsFree full text
  5. Prognostic significance of anthropometric measurements in gastric cancer: a multicenter cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Trials on ClinicalTrials.gov6
  1. Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled TrialNot yet recruitingNCT07561073Lead sponsorN/AStart 2026-10
  2. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  3. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)RecruitingNCT07221149Study sitePhase 2/Phase 3Start 2026-03
  4. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06
  5. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  6. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
1.3%Leads about 1 in 77 of China's research papers on Hepatoblastoma

Led 2 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
2.3%Leads about 1 in 44 of China's research papers on Osteosarcoma ▲ from 1.1%

Led 51 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
51
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.0%Leads none of China's research papers on Gastrointestinal stromal tumour

Led 0 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.4%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 4 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University3
  2. Second Affiliated Hospital of Guangxi Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
2.5%Leads about 1 in 41 of China's research papers on Ewing sarcoma ▲ from 1.2%

Led 4 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. First Clinical Affiliated Hospital of Guangxi Medical University2
  2. Guangxi Medical University Cancer Hospital1
  3. First Affiliated Hospital of Guangxi Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.7%Leads under 1 in 100 of China's research papers on Myeloma

Led 11 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025
ThemesDiagnosis, MRD & riskStem cell transplantDrug combinations

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University11

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Active Epstein-Barr virus infection and its association with multiple myeloma: evidence from a meta-analytical perspective.2025Hematology (Amsterdam, Netherlands)
  2. Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma.2025Hematology (Amsterdam, Netherlands)
  3. Correlation analysis of laboratory indicators, genetic abnormalities and staging in patients with newly diagnosed multiple myeloma.2024MedicineFree full text
  4. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.2023Hematology (Amsterdam, Netherlands)
  5. Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma.2021Technology in cancer research & treatmentFree full text
Trials on ClinicalTrials.gov6
  1. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  2. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  3. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  4. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  5. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  6. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.8%Leads under 1 in 100 of China's research papers on HLH

Led 3 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025
ThemesLymphoma & cancer-related HLHEBV & infection triggersTreatment regimens

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
9.3%Leads about 1 in 11 of China's research papers on Beta thalassaemia

Led 29 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
1
Research papers it led
29
Trials it led
5
Share of China's trials
10.6%
Share of the world's papers
1.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
Papers it led5
  1. Effects of Thalidomide on Metabolism and Lifespan of Red Blood Cell in Patients With β-Thalassemia Major: A Post Hoc Analysis of a Randomized Controlled Trial.2025Clinical therapeuticsRCT
  2. Whole-Brain Analysis of Increased Brain Iron in Patients with β-Thalassemia.2025Academic radiology
  3. White matter microstructure abnormalities in thalassemia patients using TBSS analysis based on DTI.2025Scientific reports
  4. Correlation study between magnetic resonance imaging-quantitated cardiac iron deposition and left ventricular function in patients with β-thalassemia major in China.2025Science progress
  5. Neuroimaging in the diagnosis and treatment of cerebral toxoplasmosis in children with severe β-thalassemia after allo-HSCT.2025Biomolecules & biomedicine
Trials on ClinicalTrials.gov6
  1. A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]RecruitingNCT05762510Lead sponsorEarly phase 1Start 2023-02
  2. A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia MajorRecruitingNCT06465550Study sitePhase 1Start 2024-01
  3. A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaRecruitingNCT06772766Study sitePhase 1Start 2024-12
  4. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingNCT04143724Study sitePhase 2Start 2019-11
  5. A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-ThalassemiaStatus unknownNCT06678165Lead sponsorEarly phase 1Start 2024-12
  6. Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical StudyCompletedNCT04009525Lead sponsorPhase 4Start 2019-07

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
1.5%Leads about 1 in 68 of China's research papers on Haemophilia A New since 2021

Led 4 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital of Guangxi Medical University2
  2. First Affiliated Hospital of Guangxi Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led4
  1. Clinical validation and application of targeted long-range polymerase chain reaction and long-read sequencing-based analysis for hemophilia: experience from a hemophilia treatment center in China.2024Journal of thrombosis and haemostasis : JTH
  2. Spectrum of Factor VIII Gene Variants in 78 Patients with Hemophilia A in Guangxi Province, China, Including Nine Novel Variants: A Descriptive Study.2025Turkish journal of haematology : official journal of Turkish Society of Haematology
  3. Detection of hemophilia A genetic variants using third-generation long-read sequencing.2024Clinica chimica acta; international journal of clinical chemistry
  4. The novel mutation p.Asp315Tyr causes severe hemophilia B by impairing coagulation factor IX expression.2021Thrombosis research
Trials on ClinicalTrials.gov5
  1. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  2. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  3. A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AActive, not recruitingNCT06297655Study sitePhase 3Start 2024-11
  4. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With InhibitorStatus unknownNCT05487976Study sitePhase 3Start 2022-04
  5. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04061109Study sitePhase 3Start 2019-05

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.6%Leads under 1 in 100 of China's research papers on NMOSD

Led 3 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
1
Share of China's trials
1.3%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025
ThemesAntibodies & diagnosisImagingPregnancy, children, older adults

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.2%Leads about 1 in 83 of China's research papers on Myasthenia gravis

Led 6 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025
ThemesAntibodies & diagnosisBiologic & complement drugsStandard immunotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University5
  2. Eighth Affiliated Hospital of Guangxi Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
1.1%Leads about 1 in 89 of China's research papers on Moyamoya ▲ from 0.4%

Led 4 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025
ThemesImaging & blood flowRevascularisation surgeryStroke & bleeding outcomes

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University4
  2. Liuzhou People's Hospital, Guangxi Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
4.9%Leads about 1 in 20 of China's research papers on Anti-NMDA receptor encephalitis ▲ from 2.4%

Led 13 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.8%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University11
  2. Liuzhou People's Hospital, Guangxi Medical University1
  3. Guangxi Medical University Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. To analyze the efficacy and safety of plasma exchange in the treatment of anti-NMDA receptor encephalitis.2026Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  2. Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report.2025BMC neurology
  3. The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity.2021Multiple sclerosis and related disorders
  4. Clinical characteristics and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor encephalitis: a retrospective, multicenter, self-controlled study.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  5. Elevated Release of Presynaptic Glutamate: The Potential Pathogenesis of Anti-NMDAR Encephalitis-Associated Seizures.2025CNS neuroscience & therapeutics

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.1%Leads about 1 in 93 of China's research papers on Takayasu arteritis New since 2021

Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Formation of Multiple Intracranial Aneurysms Caused by Takayasu Arteritis.2024Radiology
  2. The diagnostic value of FDG PET/CT in Takayasu arteritis.2022Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.4%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 4 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Guangxi Medical University2
  2. First Affiliated Hospital of Guangxi Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.3%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis New since 2021

Led 2 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.03%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.9%Leads about 1 in 53 of China's research papers on Duchenne muscular dystrophy

Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University2
  2. Second Affiliated Hospital of Guangxi Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.7%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 5 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.7%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis New since 2021

Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Guangxi Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov